Drug Profile

HNC 042

Alternative Names: HNC-042; ZBD-042; ZBD-1042

Latest Information Update: 10 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Guangzhou Henovcom Bioscience
Developer Guangzhou Henovcom Bioscience; Heilongjiang Zhenbaodao Pharmaceutical
Class Antivirals
Mechanism of Action Neuraminidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Oct 2025 Heilongjiang Zhenbaodao Pharmaceutical plans a phase II trial for Influenza virus infections (Heilongjiang Zhenbaodao Pharmaceutical pipeline, October 2025)
28 Jul 2022 No recent reports of development identified for phase-I development in Influenza-virus-infections in USA (IV, Injection)
18 Jul 2022 Phase-II clinical trials in Influenza virus infections prevention in China (IV) before July 2022 (Heilongjiang Zhenbaodao Pharmaceutical, July 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com